Sort
15,273 grants matching “antimicrobial resistance”
Biology of Infectious Diseases Training Program
$241,471Henry F Chambers · University Of California, San Francisco · T32 · FY2007 · AI
Biology of Infectious Diseases Training Program
$241,471Henry F Chambers · University Of California, San Francisco · T32 · FY2008 · AI
Antimicrobial blue light-activatable optical endotracheal tube to combat biofilms on the endotracheal tube
$241,455Tianhong Dai · Massachusetts General Hospital · R21 · FY2025 · AI
Benzophenones: Novel natural agents which inhibits HIV and Candida
$241,413Ramiro Mendonca Murata · University Of Southern California · R00 · FY2014 · AT
Benzophenones: Novel natural agents which inhibits HIV and Candida
$241,411Ramiro Mendonca Murata · University Of Southern California · R00 · FY2013 · AT
Optogenetic Control of Bacterial Persistence to Study Biomaterial Infections
$241,350Dacheng Ren · Syracuse University · R21 · FY2024 · AI
Strategies for generating high affinity antibodies against Gram negative bacteria
$241,272M.g. Finn · Georgia Institute Of Technology · R21 · FY2021 · AI
The microbiome as a risk factor for periprosthetic joint infection
$241,239Mathias P.g. Bostrom · Hospital For Special Surgery · R21 · FY2017 · AR
Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics
$241,150Kyle H Rohde · University Of Central Florida · R21 · FY2021 · AI
Crystalline Endolysin Treatment for Tuberculosis in TB/HIV co-infected patients
$241,150Bhami Shenoy · Procrysta Biologix, Inc. · R43 · FY2011 · AI
Hybrid nanoparticles as highly efficient photosensitizers for the treatment of topical bacterial infections
$241,018Peng Zhang · Alph Technologies, Llc · R41 · FY2020 · AI
Expansion of spectrum of activity of pleuromutilin for MDR Gram-negative bacteria
$241,000Michio Kurosu · University Of Tennessee Health Sci Ctr · R21 · FY2015 · AI
Novel strategies for treatment of Mycobacterium abscessus pulmonary disease
$240,878Susan E Dorman · Medical University Of South Carolina · R34 · FY2025 · AI
INTERACTION OF ORAL SPIROCHETES WITH GINGIVAL EPITHELIUM
$240,850University Of Washington · R01 · FY2004 · DE
Disrupting Biofilm Formation to Improve TB Drug Treatment
$240,768Randall J Basaraba · Colorado State University · R01 · FY2017 · AI
Small molecule inhibitors of lytic transglycosylase to potentiate beta-lactam antibiotics
$240,750Focco Van Den Akker · Case Western Reserve University · R21 · FY2020 · AI
Delineating adaptive mechanisms of tick-borne relapsing fever spirochetes within the argasid vector.
$240,750Job E Lopez · Baylor College Of Medicine · R21 · FY2024 · AI
Combinatorial approach to develop novel pre-therapeutic agents targeting virulence factors essential to clinically relevant pathogens
$240,709Hanh Ngoc Lam · Virginia Polytechnic Inst And St Univ · R00 · FY2023 · AI
Effector-triggered immunity against Legionella pneumophila in dendritic cells
$240,625Sunny Shin · University Of Pennsylvania · R21 · FY2023 · AI
In Vivo Efficacy Studies of Clofazimine against CDAD in Hamster Model
$240,553Sharanjit Ks Vedbrat · Kamtek, Inc. · R43 · FY2016 · AI
Evolution of KPC-K pneumoniae that persist in patients on prolonged antibiotics
$240,511Cornelius J Clancy · University Of Pittsburgh At Pittsburgh · R21 · FY2016 · AI
INJECTABLE, TUNABLE CO-DELIVERY THERAPEUTIC IMPLANT TO REDUCE AIRWAY STENOSIS
$240,372Yoonjee Park · University Of Cincinnati · R21 · FY2025 · EB
Surface protein dynamics in live bacterial pathogens
$240,311Julie A. Theriot · Stanford University · R01 · FY2009 · AI
Trans-Tympanic Drug Delivery for Treatment and Prophylaxis of Otitis Media
$240,299Rong Yang · Cornell University · R00 · FY2021 · DC
Periplasmic Zinc Management and Homeostasis in Paracoccus denitrificans
$240,269Erik T Yukl · New Mexico State University Las Cruces · R01 · FY2019 · GM